Compare Abeona Therapeutics Inc (ABEO) vs SoundHound AI Inc (SOUN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs SoundHound AI Inc — how do they compare? Abeona Therapeutics Inc trades at $7.37 (market cap $421.19M), while SoundHound AI Inc trades at $7.39 (market cap $3.29B). The key difference: SoundHound AI Inc is far larger — about 7.8× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, SoundHound AI Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | SOUN | |
|---|---|---|
Market Cap | $421.19M | $3.29B |
Sector | Health | Technology |
52-Week High | $7.45 | $21.40 |
52-Week Low | $4.17 | $5.70 |
Enterprise Value | $276.10M | $3.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.365, down 1.14% today, amid a bullish technical outlook with moving averages signaling strength. The company reported a net income of $71.18 million in 2025, with a net margin of 454.86%, though revenue remains modest at $5.82 million. Recent news includes CMS granting NTAP status for ZEVASKYN and expanding its treatment center network, indicating commercial progress.
The outlook is supported by strong analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high SG&A expenses relative to revenue and a shareholder investigation. Upside hinges on revenue scaling to justify current valuations, with the Q2 2026 earnings call on August 13, 2026, as a key near-term catalyst.
SoundHound AI (SOUN) trades at $7.395, down 0.87% today, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings beat expectations, revenue grew 45% year-over-year to $61.9 million, and the company raised its 2026 revenue guidance, driven by its OASYS platform. However, the stock faces headwinds from negative net income margins and high cash burn.
The outlook is cautiously optimistic with 75% of analysts rating it Buy and a $8.50 consensus target, but profitability challenges and premium valuations pose risks. Key catalysts include the pending LivePerson acquisition and OASYS adoption, while execution on path to profitability remains critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About SoundHound AI Inc
SoundHound AI, Inc. is a leading innovator in voice artificial intelligence, specializing in conversational intelligence technology. The company develops a platform that allows businesses to add custom voice assistants and natural language processing capabilities to their products and services, ranging from in-car systems and smart speakers to mobile apps and IoT devices. SoundHound's core technology, including its proprietary speech recognition and natural language understanding models, aims to enable fast, accurate, and deeply integrated voice AI experiences across various industries.
Read more on SOUN →
